AMGEN Inc.

NASDAQ:AMGN   4:00:00 PM EDT
283.29
-1.62 (-0.57%)
6:12:25 PM EDT: $284.88 +1.59 (+0.56%)
Products

FDA Investigating Risk Of Severe Hypocalcemia In Patients On Dialysis Receiving Osteoporosis Medicine Prolia (Denosumab)

Published: 11/22/2022 15:03 GMT
AMGEN Inc. (AMGN) - FDA Investigating Risk of Severe Hypocalcemia in Patients on Dialysis Receiving Osteoporosis Medicine Prolia (denosumab).
FDA - Investigating Risk of Severe Hypocalcemia With Serious Outcomes in Patients With Advanced Kidney Disease on Dialysis Treated With Prolia.
FDA - Serious Outcomes Include Hospitalization and Death in Patients With Advanced Kidney Disease on Dialysis Treated With Prolia.
FDA - Review of Interim Results From Ongoing Safety Study of Prolia Suggests Increased Risk of Hypocalcemia in Patients With Advanced Kidney Disease.
FDA - Are Alerting Health Care Professionals, Continuing to Evaluate Potential Safety Issue With Prolia Use in Patients With Advanced Kidney Disease.
((reuters.
Briefs@thomsonreuters.
Com;)).